Cited by 501

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver diseasePowell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years [Hepatology 1990; 11:74–80]

Caldwell, Stephen H, Crespo, Deborah M·2004·Journal of Hepatology

DOI 10.1016/j.jhep.2004.02.013

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2004.02.013

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394

Show all 3 references

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
Epidemiology of Non-Alcoholic Fatty Liver Disease
Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010) · Digestive Diseases · doi:10.1159/000282080 · Cited by 1,026
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2300 · Cited by 554
Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link
Siegel, A. B., & Zhu, A. X. (2009) · Cancer · doi:10.1002/cncr.24687 · Cited by 399
Obesity-Associated Liver Disease
Marchesini, G., Moscatiello, S., Di Domizio, S., & Forlani, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1399 · Cited by 359
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Nonalcoholic fatty liver disease and aging: epidemiology to management.
Bertolotti, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14185 · Cited by 270
Hepatic Steatosis: A Mediator of the Metabolic Syndrome. Lessons From Animal Models
den Boer, M., Voshol, P. J., Kuipers, F., Havekes, L. M., & Romijn, J. A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000116217.57583.6e · Cited by 260
Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study
Caiazzo, R., Lassailly, G., Leteurtre, E., Baud, G., Verkindt, H., Raverdy, V., Buob, D., Pigeyre, M., Mathurin, P., & Pattou, F. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000945 · Cited by 226
Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame
Ibrahim, S. H., Hirsova, P., Malhi, H., & Gores, G. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3977-1 · Cited by 218
Nonalcoholic fatty liver disease
Erickson, S. K. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800089-jlr200 · Cited by 194
Association between serum ferritin and the insulin resistance syndrome in a representative population
Wrede, C. E., Buettner, R., Bollheimer, L. C., Schölmerich, J., Palitzsch, K.-D., & Hellerbrand, C. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02083 · Cited by 161
Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity
Lonardo, A., Mantovani, A., Lugari, S., & Targher, G. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.03.001 · Cited by 150
Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease
Reilly, N. R., Lebwohl, B., Hultcrantz, R., Green, P. H. R., & Ludvigsson, J. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.013 · Cited by 110
Etiology of Liver Cirrhosis in Mexico
Méndez-Sánchez, N., Aguilar-Ramírez, J. R., Reyes, A., Dehesa, M., Juárez, A., Castañeda, B., Sánchez-Avila, F., Poo, J. L., Guevara González, L., Lizardi, J., et al. (2004) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32122-2 · Cited by 106
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Body Roundness Index and Waist-to-Height Ratio are Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based Study
Motamed, N., Rabiee, B., Hemasi, G. R., Ajdarkosh, H., Khonsari, M. R., Maadi, M., Keyvani, H., & Zamani, F. (2016) · Hepatitis Monthly · doi:10.5812/hepatmon.39575 · Cited by 80
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2013 · Cited by 59
Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection
Mak, L.-Y., Hui, R. W.-H., Fung, J., Liu, F., Wong, D. K.-H., Li, B., Cheung, K.-S., Yuen, M.-F., & Seto, W.-K. (2021) · Hepatology International · doi:10.1007/s12072-021-10218-2 · Cited by 58
SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
Dwinata, M., Putera, D., Hasan, I., & Raharjo, M. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.102173 · Cited by 51
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
Iyer, J. S., Juyal, D., Le, Q., Shanis, Z., Pokkalla, H., Pouryahya, M., Pedawi, A., Stanford-Moore, S. A., Biddle-Snead, C., Carrasco-Zevallos, O., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03172-7 · Cited by 54

Authors: Caldwell, S. H., & Crespo, D. M.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2004-04
Volume: 40
Issue: 4
Pages: 578-584
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2004.02.013
OpenAlex: W2001869632
Cited by: 501
References: 3
FWCI: 22.06
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review